NCT05190445: A trial that was reported late by Pieris Pharmaceuticals, Inc.
This trial has reported, although it was 75 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05190445 |
|---|---|
| Title | A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 1, 2021 |
| Completion date | Feb. 1, 2023 |
| Required reporting date | Feb. 1, 2024, midnight |
| Actual reporting date | April 16, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 75 |